i have just read kv pharmaceuticals quarterly report just issued.in summary the report said that evamist has increased from 2000 new prescriptions on its launch to trending towards 4000 prescriptions per month now.evamist is currently the second most prescribed new transdermal product in the estrogen category.evamist continues to receive positive feedback from physicians and patients alike.kv has stated that it believes that evamist will be a significant contributor to their revenue during the second half of fiscial 2009 (they must be very confident).(FULL REPORT IS WORTH READING)
Add to My Watchlist
What is My Watchlist?
